{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$4.83 vs. cons $4.78",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Enterprise revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$3.740B vs. cons $3.714B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Quarterly BLS book-to-bill",
      "prediction": "MISS",
      "answer": "pred ~1.10x vs. cons 1.121x",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 enterprise revenue",
      "prediction": "UNCHANGED",
      "answer": "guide ~$14.65B-$14.80B vs. cons $14.716B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 adjusted EPS",
      "prediction": "UNCHANGED",
      "answer": "guide ~$17.70-$18.35 vs. cons $18.05",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "BLS / ED commentary (FY26)",
      "prediction": "UNCHANGED",
      "answer": "reaffirm Central Labs mid-single-digit growth; ED flat with stronger 2H vs. UNVERIFIED consensus",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -4.5,
  "day1_confidence": "LOW",
  "day5_residual_pct": -5.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 unchanged FY guide implies modestly softer H2 estimates",
  "day5_confidence": "LOW"
}